Search Results 1231-1240 of 13318 for monoclonal antibody

1. Medical Research & Education - Mayo Clinic News Network

   Antibody-drug conjugates are targeted cancer therapies. They deliver potent drugs directly into cancer cells while minimizing harm to healthy tissue. These ...

2. Atezolizumab Immunotherapy In Patients With Advanced NSCLC (AJCC 7th Edition) - Mayo Clinic

   Prior severe infusion reaction to a monoclonal antibody. Severe, active co-morbidity, defined as follows: Significant history of uncontrolled cardiac ...

3. A Study To Assess Adverse Events Of Intravenously (IV) Infused ABBV-383 In Adult Participants With Relapsed Or Refractory Multiple Myeloma - Mayo Clinic

   ... monoclonal antibody. Exclusion Criteria: - Received B-cell maturation antigen (BCMA)-targeted therapy. Note: Other protocol defined Inclusion/Exclusion ...

4. A Study of AO-176 as Monotherapy Combinated with Bortezomib and Dexamethasone in Adults with Relapsed or Refractory Multiple Myeloma - Mayo Clinic

   ... monoclonal antibodies, and not a candidate for ... antibody syndrome. Patients receiving dual ... antibody positive, confirmed by HCV ribonucleic acid).

5. Mayo Clinic discovery of breast cancer treatment resistance can lead to new hope for some

   Mayo Clinic researchers have identified a key mechanism behind resistance to antibody-drug conjugate therapies in some HER2+ breast cancers.

6. A Study Testing The Combination Of Dasatinib Or Imatinib To Chemotherapy Treatment With Blinatumomab For Children, Adolescents, And Young Adults With Philadelphia Chromosome Positive (Ph+) Or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL) - Mayo Clinic

   An antibody is a protein made by the immune system to help fight infections and other harmful processes/cells/molecules. Blinatumomab may bind to the cancer ...

7. A Study To Evaluate The Effectiveness And Safety Of RAd-IFN Administered With Celecoxib And Gemcitabine In Patients With Malignant Pleural Mesothelioma - Mayo Clinic

   Monoclonal antibody, at least 3 half-lives from last dose;; Non-antibody immunotherapy (e.g., tumor vaccine), at least 42 days from last dose ...

8. A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma - Mayo Clinic

   About this study. This study is researching an experimental drug called fianlimab (also known as REGN3767), combined with another medication called ...

9. A Study of the Safety, Tolerability, and Drug/Body Interactions of C2N-8E12 in People with Progressive Supranuclear Palsy - Mayo Clinic

   ... antibody HJ8.5. We sought to determine the effects of ... monoclonal antibodies for their ability to block seeding activity present in P301S brain lysates.

10. A Study To Evaluate EAA181 To Treat Newly-diagnosed Multiple Myeloma - Mayo Clinic

    ≥ 1 g/dL monoclonal protein (M-protein) on serum protein electrophoresis; ≥ 200 mg/24 hours of monoclonal protein on a 24-hour urine protein electrophoresis.